CNSP - CNS Pharmaceuticals, Inc.

2.94
-0.060   -2.041%

Share volume: 22,731
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.00
-0.06
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 8%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.07%
1 Month
-31.15%
3 Months
-59.22%
6 Months
-53.99%
1 Year
10.94%
2 Year
569.70%
Key data
Stock price
$2.94
P/E Ratio 
0.00
DAY RANGE
$2.88 - $3.15
EPS 
-$14.01
52 WEEK RANGE
$0.66 - $10.59
52 WEEK CHANGE
$13.08
MARKET CAP 
5.171 M
YIELD 
N/A
SHARES OUTSTANDING 
620.290 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-21-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
2.15
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,282
AVERAGE 30 VOLUME 
$21,187
Company detail
CEO: John M. Climaco
Region: US
Website: cnspharma.com
Employees: 5
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CNS Pharmaceuticals, Inc. engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials.

Recent news